Related Experiment Video
Updated: Sep 3, 2025
Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
Published on: August 2, 2022
Effectiveness and safety of PRP on persistent olfactory dysfunction related to COVID-19
Younès Steffens1, Serge-Daniel Le Bon2,3, Jerome Lechien2
1Department of Otorhinolaryngology, CHU Saint-Pierre, Rue aux Laines 105, 1000, Brussels, Belgium. younes.steffens@stpierre-bru.be.
Introduction:
Olfactory dysfunction (OD) is a well know symptom of coronavirus disease 2019 (COVID-19), accounting for 48 to 85% of patients. In 1 to 10% of cases, patients develop a chronic olfactory dysfunction (COD), lasting more than 6 months. Recently, platelet-rich plasma (PRP) was used in patients with non-COVID-19 COD and authors reported encouraging results.
Methods:
In the present study, we investigated the usefulness and safety of PRP injection in 56 patients with COVID-19 COD by the Sniffing Stick test (TDI score) and a linker-scale from 0 (none) to 3 (strong) and we compare the result to a control group.
Results:
At 1 month post-PRP injection, the mean TDI scores significantly improved by 6.7 points in the PRP group (p < 0,001), the mean self-assessment of improvement in smell function was 1.8 (mild-to-moderate) in the PRP group, which was significantly higher than the score (0.3) in the control group (p < 0,001).
Conclusion:
Our results showed that PRP in the olfactory cleft can increase the olfactory threshold 1 month after the injection. Moreover, our results suggest that timing of treatment may be an important factor and that PRP is a safe treatment, because no adverse effects were reported throughout the study.
Trial Registration Number:
NCT05226546.
